| Metric | Value (₹ Cr) | vs Q1 FY26 |
|---|---|---|
| Revenue | 143.59 | 20.3% |
| Total Income | 145.29 | 21.2% |
| Expenditure | 132.59 | 19.6% |
| PBT | 12.71 | 40.5% |
| Net Profit | 9.43 | 39.4% |
| OPM | 14.36% | 0.51pp |
| NPM | 6.49% | 0.85pp |
| EPS | 19.98 | 39.4% |
Fredun Pharmaceuticals Reports 61% YoY Growth in EBITDA to ¥39.33 Cr in H1 FY26
10 Nov 2025 · 10 Nov 2025, 07:42 pm
Summary
Fredun Pharmaceuticals Limited, a leading pharmaceuticals formulation manufacturing company in India, has reported its unaudited financials for Q2 FY26 & H1 FY26. The company reported a YoY growth of 35.34% in total income and 60.98% in EBITDA for H1 FY26.
Key Highlights
- 1
Total Income for Q2 FY26 was ¥145.29 Cr, a YoY growth of 35.34%
- 2
EBITDA for Q2 FY26 was ¥22.34 Cr, a YoY growth of 60.09%
- 3
Net Profit for Q2 FY26 was ¥9.73 Cr, a YoY growth of 127.75%
- 4
The company has commenced expansion of its state-of-the-art manufacturing facility at Palghar
- 5
Launched Snacky Jain—India’s first Jain functional food for pets
- 6
Acquired Wagr.ai and One Pet Stop, expanding footprint across nutrition, technology, and services
Management Comments
Fredun Nariman Medhora
Q2 FY26 was a strong quarter for Fredun, driven by consistent growth across our pharmaceutical and pet care verticals... We reported improved cash flows this quarter, driven by efficient execution and disciplined operations... We aim to scale our operations, accelerate new product launches, and strengthen our digital-first platforms to enhance accessibility and experience for pet parents... With a clear strategy, strong execution, and first-mover advantage, we remain confident of sustaining our growth momentum and building long-term value for all
Informational and educational content only. Not investment advice.